Kidney regeneration and repair after transplantation

PURPOSE OF REVIEW: To briefly show which are the mechanisms and cell types involved in kidney regeneration and describe some of the therapies currently under study in regenerative medicine for kidney transplantation. RECENT FINDINGS: The kidney contains cell progenitors that under specific circumstances have the ability to regenerate specific structures. Apart from the knowledge gained in the self-regenerative properties of the kidney, new concepts in regenerative medicine such as organ engineering and the use of mesenchymal stem cell-based therapies are currently the focus of attention in the field. SUMMARY: Overall, kidney regeneration is a reality and the knowledge on how to control it will be one of the main scopes in the present and future

Rediscovery of Cereopsis studeri Koch, 1891, a forgotten Mediterranean soft coral species, and its inclusion in the genus Nidalia Gray, 1835 (Octocorallia, Alcyonacea, Nidaliidae)

Cereopsis studeri was described by G. von Koch in 1891 with material from Naples. However, it was subsequently synonymized, erroneously identified, and overlooked in subsequent soft coral literature of the twentieth century. After the original description, this species was not recorded or correctly described for 120 years. The study of newly collected material from the North Western Mediterranean permits the re-description of this forgotten species and its assignation to the genus Nidalia in the family Nidaliidae. The main features of Nidalia studeri com. nov. are: colony torch-like, a capitulum light orange in colour, not laterally flattened, dome-shaped and not distinctly projecting beyond the stalk, introvert with sclerites transversally placed in two longitudinal rows per interseptal space, anthocodial crown with 28–38 sclerite rows, points separated from polyps distally, formed by 6–9 pairs of sclerites, and the presence of intermediate points (secondary points) between principal (interseptal) ones. Nidalia studeri is here compared with its closest congeners, especially with the Indonesian species N. simpsoni, species from the West Indian Region N. dissidens, N.occidentalis, N. deichmannae, and the recently described Nidalia aurantia from the Mid-Atlantic Ocean. This is the first time that the genus Nidalia and the family Nidaliidae have been reported with certainty for the Mediterranean Sea

Morphological features of the gorgonian Paramuricea macrospina on the continental shelf and shelf edge (Menorca Channel, Western Mediterranean Sea)

Morphological variability in gorgonians is frequent and commonly associated with habitat variability, often resulting in segregated morphotypes. Paramuricea macrospina is an endemic Mediterranean gorgonian species found on rocky bottoms between 40 and 160 m depth and has recently been reported as one of the most abundant species in continental shelf and shelf edge environments. Three different chromatic forms of P. macrospina were observed in the Menorca Channel: a yellow form and a light purple form occurring on maërl beds of the continental shelf, and a dark purple form occurring on rocky substrates of the shelf edge. The objective of the present work is to verify if these P. macrospina forms may represent distinct taxonomic units by analysing differences in colony morphology and sclerite size and shape of the three chromatic forms. No significant differences were found in colony shape, suggesting that environmental variability between the continental shelf and the shelf edge is not influential enough to significantly alter colony morphology. Significant differences in sclerite size and shape were found amongst all forms, suggesting that sclerites may be influenced by environmental conditions. However, the co-occurrence of the yellow and light purple forms side by side on the continental shelf may indicate a certain degree of genetic differentiation

Update on controls for isolation and quantification methodology of extracellular vesicles derived from adipose tissue mesenchymal stem cells

The research field on extracellular vesicles (EV) has rapidly expanded in recent years due to the therapeutic potential of EV. Adipose tissue human mesenchymal stem cells (ASC) may be a suitable source for therapeutic EV. A major limitation in the field is the lack of standardization of the challenging techniques to isolate and characterize EV. The aim of our study was to incorporate new controls for the detection and quantification of EV derived from ASC and to analyze the applicability and limitations of the available techniques. ASC were cultured in medium supplemented with 5% of vesicles-free fetal bovine serum. The EV were isolated from conditioned medium by differential centrifugation with size filtration (0.2 μm). As a control, non-conditioned culture medium was used (control medium). To detect EV, electron microscopy, conventional flow cytometry, and western blot were used. The quantification of the EV was by total protein quantification, ExoELISA immunoassay, and Nanosight. Cytokines and growth factors in the EV samples were measured by multiplex bead array kit. The EV were detected by electron microscope. Total protein measurement was not useful to quantify EV as the control medium showed similar protein contents as the EV samples. The ExoELISA kits had technical troubles and it was not possible to quantify the concentration of exosomes in the samples. The use of Nanosight enabled quantification and size determination of the EV. It is, however, not possible to distinguish protein aggregates from EV with this method. The technologies for quantification and characterization of the EV need to be improved. In addition, we detected protein contaminants in the EV samples, which make it difficult to determine the real effect of EV in experimental models. It will be crucial in the future to optimize design novel methods for purification and characterization of EV

Mesenchymal stem cells in solid organ transplantation (MiSOT) fourth meeting: Lessons learned from first clinical trials

The Fourth Expert Meeting of the Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Consortium took place in Barcelona on October 19 and 20, 2012. This meeting focused on the translation of preclinical data into early clinical settings. This position paper highlights the main topics explored on the safety and efficacy of mesenchymal stem cells as a therapeutic agent in solid organ transplantation and emphasizes the issues (proper timing, concomitant immunossupression, source and immunogenicity of mesenchymal stem cells, and oncogenicity) that have been addressed and will be followed up by the MiSOT Consortium in future studies

Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

There is limited clinical evidence on the utility of the monitoring of Epstein-Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients